Patrícia Silva, PhD,  director of science content—

Clinical-stage biopharmaceutical company N30 Pharmaceuticals, Inc. has named Jon Congleton as the new President and Chief Executive Officer (CEO), as well as a member of the company’s board of directors. Boulder, Colorado-based N30 Pharma is focused on the development of new treatment options for cystic fibrosis (CF), and was the first research company to discover small…

Galapagos NV, a developmental stage biotechnology company working on small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic diseases, announced it has launched the first Phase I study of GLPG1837, a potentiator formulated as a CFTR-targeted therapy for cystic fibrosis (CF) cases caused by class III/IV mutations. In order…

The Cystic Fibrosis Trust recently announced that it would serve as the official charity partner of the British Comedy Awards for their 25th Anniversary special on December 17, 2014. Before the ceremony officially began, a very special video from the Trust made its debut in front of a star-studded…

The All-Party Parliamentary Group (APPG) on Cystic Fibrosis was officially launched this Tuesday in the United Kingdom’s House of Commons, with support from politicians and policy makers across the entire political spectrum in the UK in endorsing the Cystic Fibrosis Trust as an effective advocate for fighting the disease…

Specialty biopharmaceutical company Shire has just announced a new partnership with the Cystic Fibrosis Foundation to develop technology that can maintain and/or restore lung function, as well as protect against respiratory infections — two primary health concerns in people living with cystic fibrosis (CF). The announcement was made…

One of the ways the Cystic Fibrosis Trust is celebrating its 50th Anniversary this year is through a month-long Thank You campaign, meant to cap off the year on a high note, and with a surge of hope. The UK not-for-profit organization created a…

Thanks to a fundraising initiative organized by the staff members of the University Hospital of South Manchester NHS Foundation Trust (UHSM), patients at the facility who suffer from cystic fibrosis (CF) now have the possibility of improving their symptoms using state-of-the-art exercise equipment, with two new, modern exercise bikes…

Drug developer Proteostasis Therapeutics, Inc., which is currently studying protein homeostasis regulation as a treatment for orphan and neurodegenerative diseases such as cystic fibrosis (CF), recently named Po-Shun Lee, MD as their new vice-president of clinical development. The pulmonary and critical care physician, who has been responsible for leading research programs on…

Virginia-based surgical and medical instrument manufacturer PulmoFlow, Inc. announced Tuesday, December 2 that the US Food and Drug Administration has granted final approval of its New Drug Application for the Kitabis Pak. The drug is a co-packaging of tobramycin inhalation solution and the PARI LC PLUS® Reusable Nebulizer, which is the first…

Corbus Pharmaceuticals has been invited to present during this Thursday’s VirtualInvestorConferences.com on its lead pipeline product Resunab™, indicated for the treatment of serious inflammatory and fibrotic diseases, namely cystic fibrosis and diffuse scleroderma. Representing the company during the upcoming online, live event is CEO Yuval Cohen,…